en · de · es
aod-9604-notes.peptides4962.com › Data › Regulatory And Analytical Context — Reference Sheet

Regulatory And Analytical Context — Reference Sheet

By Editorial Desk · published 2026-01-06 · last reviewed 2026-02-23 · Data

Everything below concerns IGF-1. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-02-23. Where a claim depends on a specific study, the study is described rather than over-claimed.

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Aod-9604 at a glance

PropertyValueNotes
Regulatory statusNot approved as a medicineStatus varies by country; prohibited in sport.
Common storage temperature2–8 °C for lyophilized powderProtect from light and moisture; follow supplier instructions.
Typical analytical methodLC-MS/MSUsed for identification and quantification in biological samples.
Purity assessmentHPLC and mass spectrometryReverse-phase HPLC is common for peptide purity.
Common synonymsAOD9604; hGH 176-191 fragmentNaming conventions differ across studies.

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

Related pages on this site

Measurement and Storage Practices

Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.

Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.

Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.

Supporting material

If necrotic tissue, subcutaneous tissue, granulation tissue, fascia, muscle or other underlying structures are visible, this indicates a full thickness pressure injury (Unstageable, Stage 3 or Stage 4). Do not use DTPI to describe vascular, traumatic, neuropathic, or dermatologic conditions. The term medical device related pressure ulcer refers to a cause rather than a classification. Pressure ulcers from a medical device are classified according to the same classification system being used for pressure ulcers arising from other causes, but the cause is usually noted. Pressure injury from medical devices on mucous membranes should not be staged.

=== Vasculogenic and Angiogenic Properties === The angiogenic effect of CGB on endothelial cells is precisely mediated through the activation of hCG/LH receptor and PKA/cAMP pathway. It is through the binding of CGB to the hCG/LH receptor that the PKA/cAMP pathway is activated, which then helps stimulate angiogenesis and the establishment of a two-way nutrient highway for the embryo and subsequent fetus. Dibutyryl cAMP then stimulates vessel outgrowth from aortic ring, which further suggests the importance of the PKA pathway, as well as its preceding CGB pathway, during this angiogenic response. And so, clear direct angiogenic effects of CGB have been observed and substantiated on endothelial cells in the aortic ring, CAM, matrigel plug, and endothelial cell proliferation. In a normal pregnancy, CGB expression is associated with endometrial stimulation of angiogenesis occurring early in gestation, while also increasing the blood supply and altering the uterine vasculature through vasodilatation, increasing permeability, development, and maturation of new vessels.

In herbal medicine, aqueous extracts of bay laurel have been used as an astringent and salve for open wounds. It is also used in massage therapy and aromatherapy. A folk remedy for rashes caused by poison ivy, poison oak, and stinging nettle is a poultice soaked in boiled bay leaves. The Roman naturalist Pliny the Elder listed a variety of conditions which laurel oil was supposed to treat: paralysis, spasms, sciatica, bruises, headaches, catarrhs, ear infections, and rheumatism.

Malatang (麻辣燙): vegetable and meat skewers served in a mala soup. For home preparation, bouillon-style cubes of instant mala have become popular. Mala Hot pot (麻辣火鍋) Mala shaokao (麻辣燒烤): mala barbecue Mala xiang guo (麻辣香鍋): mala stirfry Mala duck neck (麻辣鴨脖子) Mouthwatering chicken (口水雞): Chicken cold cuts in mala sauce Fuqi feipian (夫妻肺片): beef tendon, tongue, tripe, and sometimes also lung, served with oily mala sauce Dapanji (大盤雞, lit. "big plate chicken"): a hearty chicken, potato and noodle stew flavored with mala

Sources: en.wikipedia.org

Supporting material

A radioactive tracer, radiotracer, or radioactive label is a synthetic derivative of a natural compound in which one or more atoms have been replaced by a radionuclide (a radioactive atom). By virtue of its radioactive decay, it can be used to explore the mechanism of chemical reactions by tracing the path that the radioisotope follows from reactants to products. Radiolabeling or radiotracing is thus the radioactive form of isotopic labeling. In biological contexts, experiments that use radioisotope tracers are sometimes called radioisotope feeding experiments. Radioisotopes of hydrogen, carbon, phosphorus, sulfur, and iodine have been used extensively to trace the path of biochemical reactions. A radioactive tracer can also be used to track the distribution of a substance within a natural system such as a cell or tissue, or as a flow tracer to track fluid flow. Radioactive tracers are also used to determine the location of fractures created by hydraulic fracturing in natural gas production. Radioactive tracers form the basis of a variety of imaging systems, such as, PET scans, SPECT scans and technetium scans. Radiocarbon dating uses the naturally occurring carbon-14 isotope as an isotopic label. In radiopharmaceutical sciences some misuse of established scientific terms exist. Therefore an international "Working Group on Nomenclature in Radiopharmaceutical Chemistry and Related Areas" was formed in 2015 by the Society of Radiopharmaceutical Sciences (SRS).

== Membrane separation processes == Membrane separation processes have a very important role in the separation industry. Nevertheless, they were not considered technically important until the mid-1970s. Membrane separation processes differ based on separation mechanisms and size of the separated particles. The widely used membrane processes include microfiltration, ultrafiltration, nanofiltration, reverse osmosis, electrolysis, dialysis, electrodialysis, gas separation, vapor permeation, pervaporation, membrane distillation, and membrane contactors. All processes except for pervaporation involve no phase change. All processes except electrodialysis are pressure driven. Microfiltration and ultrafiltration is widely used in food and beverage processing (beer microfiltration, apple juice ultrafiltration), biotechnological applications and pharmaceutical industry (antibiotic production, protein purification), water purification and wastewater treatment, the microelectronics industry, and others. Nanofiltration and reverse osmosis membranes are mainly used for water purification purposes. Dense membranes are utilized for gas separations (removal of CO2 from natural gas, separating N2 from air, organic vapor removal from air or a nitrogen stream) and sometimes in membrane distillation. The later process helps in the separation of azeotropic compositions reducing the costs of distillation processes.

Melitta Schmideberg-Klein (née Klein; 17 January 1904 – 10 February 1983), author of numerous books, academic papers and monographs; physician, psychiatrist, and psychoanalyst; daughter of leading psychoanalyst Melanie Klein; associate member of British Psychoanalytical Society and underwent analysis with Edward Glover, Hanna Segal (1918–2011), psychoanalyst of Polish Jewish descent; follower of Melanie Klein; president of British Psychoanalytical Society, vice-president of International Psychoanalytical Association; was appointed to the Freud Memorial Chair at University College, London (UCL); considered the doyen of "classical" Kleinian thinking and technique" and "one of the most distinguished psychological theorists of our time " Judah Segal, FBA (21 June 1912 – 23 October 2003, prolific author, scholar and academic; Professor of Semitic Languages at the School of Oriental and African Studies.His father was Professor Moshe Zvi Segal, Israeli rabbi, linguist and Talmudic scholar; his brother was Labour Party politician Samuel Segal; father of University of London scholar, Professor Naomi Segal. Lynne Segal (born 29 March 1944) socialist feminist academic and activist; author of over ten books and numerous scholarly monographs on ideology and geopolitics; Professor of Psychology and Gender Studies at Birkbeck, University of London, where she now works in The School of Psychosocial Studies.

Sources: en.wikipedia.org

Frequently asked questions

Is AOD-9604 approved for medical use?

No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.

Why is it banned in sports?

The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.

How is AOD-9604 detected?

Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Network